TLR2

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Retrieved on: 
Wednesday, April 19, 2023
NOD2, AACR, Therapy, Neoplasm, Cancer, American Association for Cancer Research, TLR9, NSAID, Breast, Research, LDC, TLR4, TLR2, Patient, NLR, TLR8, Poster, Metastasis, Pharmaceutical industry, Vaccine

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.
  • The poster, titled, “ A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy ,” authored by Michael J. Newman, Ph.D., the Company’s Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023.
  • Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
  • Importantly, our results demonstrate the potential for activity in multiple solid tumor indications with high unmet need and the flexibility to be combined with a wide variety of synergy partners.

Newly Developed RSV Vaccine Offers Immunity While Lowering the Risk of Dangerous Pulmonary Inflammation

Retrieved on: 
Monday, January 30, 2023
ACT, Safety, TLR2, University, Malaria, Veterinary medicine, Immunology, Inflammation, Bangladesh Technical Education Board, University of Georgia College of Veterinary Medicine, Viral, Immunity, Infection, National Institute of Allergy and Infectious Diseases, Volunteering, RSV, Vaccine, Protein, Mouse, T helper cell, Bronchiolitis, Volume Ten, Pneumonia, Clinical trial, Eosinophil, Antibody, LBL, Research, CHMI, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Jan. 30, 2023 /PRNewswire/ -- Scientists at Artificial Cell Technologies (ACT) have developed a fully synthetic microparticle vaccine for Respiratory Syncytial Virus (RSV)  that elicited a protective immune response in mice while simultaneously lowering pulmonary inflammation after exposure to the virus. New results of their preclinical research have been published in the journal Vaccines.

Key Points: 
  • A major risk of RSV infection is the potential for severe pulmonary inflammation characterized by bronchiolitis and pneumonia.
  • In the 1960s, clinical trials of a formalin-inactivated (FI-RSV) vaccine were halted when more vaccinated children were hospitalized after RSV infection compared to those who were not vaccinated.
  • "An effective RSV vaccine must protect against infection without priming the host for excessive inflammation," says Jeff Powell, Ph.D., Vice President of Immunology at ACT.
  • ACT is currently preparing for a Phase 1b controlled human malaria infection (CHMI) clinical trial of its malaria vaccine.

Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research to Support Development of Its TLR2 Program

Retrieved on: 
Tuesday, April 19, 2022
Technology, Medical Devices, Genetics, Clinical Trials, Nanotechnology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, The Michael J. Fox Foundation, TLR2, Disease, MJFF, Neurodegeneration, Therapy, Pharmaceutical industry, Neurulation

The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule Toll-Like receptor 2 (TLR2) antagonist.

Key Points: 
  • The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule Toll-Like receptor 2 (TLR2) antagonist.
  • TLR2 plays an important role in creating and maintaining a harmful neuro-inflammatory condition in Parkinsons disease.
  • Reducing this neuroinflammation, by blocking TLR2, has the potential to prevent neurodegeneration and slow the progression of the disease.
  • This grant will help enable us to rapidly advance our lead TLR2 antagonist through preclinical and early clinical development, stated Douglas Bonhaus, Chief Executive Officer of Neuropore.

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Retrieved on: 
Monday, January 17, 2022
Atopic dermatitis, Patient, Research, TLR2, Inflammation, Confidentiality, Clinical trial, Private Securities Litigation Reform Act, SEC, COVID-19, Oral medicine, Effectiveness, Growth, Risk, GLOBE, Ownership, Psoriasis, Immunosuppression, Marketing, Preclinical development, Pharmacology, Immune system, Failure, Pharmaceutical industry, Vaccine, T helper cell, Dermatology

The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.

Key Points: 
  • The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.
  • The data presented today build on the substantial evidence accumulated through our clinical and preclinical work, deepening our understanding of the mechanism by which EDP1815 drives its clinical effects.
  • B.Chir, Dermatology and Pharmacology Physician at Addenbrookes Hospital and Immunology Clinical Lead of Evelo.
  • Evelo currently has three product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases.

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

Retrieved on: 
Tuesday, September 28, 2021
Biotechnology, Mouse, Partnership, European Respiratory Journal, TLR2, Vaccine, Nose, Interview, Infection, Patient, PPD, Inc., Nasal mucosa, Chronic Respiratory Disease, American Society for Clinical Investigation, Â, Virus, ENA, CEO, Immunodeficiency, Ageing, PPD, Risk, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Pharming, Incidence, Safety, Viral load, Epithelium, Frontiers Media, United Kingdom, RSV, GLOBE, Pharmaceutical industry

SYDNEY, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) -- ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has engaged research partners PPD, Inc. and hVIVO, a division of Open Orphan, to conduct its Phase 2 studies. The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. This announcement follows encouraging preliminary results from the ongoing Phase 1 study which supports decision to progress INNA-051 development to Phase 2 studies.

Key Points: 
  • The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin.
  • This announcement follows encouraging preliminary results from the ongoing Phase 1 study which supports decision to progress INNA-051 development to Phase 2 studies.
  • The study will also evaluate whether the nasal spray reduces the magnitude and duration of SARS-CoV-2 nasal shedding, to understand potential broader public health benefits.
  • These Phase 2 studies will take us closer to understanding whether our nasal spray can prevent illness and reduce the risk of community spread of common respiratory viruses.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Respiratory diseases, Zoonoses, Sarbecovirus, Atypical pneumonias, Bat virome, COVID-19, Occupational safety and health, TLR2, Severe acute respiratory syndrome, COVID-19 vaccine

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points: 
  • By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
  • The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
  • The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Retrieved on: 
Tuesday, June 15, 2021
Sarbecovirus, Respiratory diseases, Medical specialties, Animal diseases, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, TLR2

The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.

Key Points: 
  • The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
  • The milestone-based financing round was jointly led by Australian life science investors Brandon Capital Partners and Minderoo Foundation, with co-investment from Uniseed.
  • We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19, said Chris Smith, Ph.D., Chairman of ENA Respiratory.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Neuropore Therapies Receives $500,000 Grant from The ALS Association to Explore ALS Treatments that Inhibit Neuronal Damage from Disease-Related Inflammation

Retrieved on: 
Monday, February 17, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Neurological disorders, Medicine, Immunology, RTT, TLR2, Immune system, Amyotrophic lateral sclerosis, Inflammation, Neuropore Therapies, Inc. (NPT®), The ALS Association

Their function is to trigger inflammation that activates the immune system in response to bad players such as viruses or bacteria.

Key Points: 
  • Their function is to trigger inflammation that activates the immune system in response to bad players such as viruses or bacteria.
  • Research suggests that TLR2 over-activation plays a key role in driving chronic inflammation that leads to the degeneration of neurons in people with ALS and Parkinsons disease.
  • We are very pleased to receive this grant from The ALS Association to facilitate the development of NPT1220-312 for the treatment of ALS.
  • The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure.